References
- Acevedo F, Camus M, Sanchez C (2015). Breast Cancer at Extreme Ages - a Comparative Analysis in Chile. Asian Pac J Cancer Prev, 16, 1455-61. https://doi.org/10.7314/APJCP.2015.16.4.1455
- Cardoso F, Costa A, Norton L, et al (2014). ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol, 25, 1871-88. https://doi.org/10.1093/annonc/mdu385
- Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-8. https://doi.org/10.1200/JCO.2010.31.2835
- Dowsett M, Sestak I, Lopez-Knowles E, et al (2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol, 31, 2783-90. https://doi.org/10.1200/JCO.2012.46.1558
- Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4. https://doi.org/10.1245/s10434-010-0985-4
- Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology, 41, 151-2. https://doi.org/10.1046/j.1365-2559.2002.14691.x
- Goldhirsch A, Winer EP, Coates AS, et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol, 24, 2206-23. https://doi.org/10.1093/annonc/mdt303
- Hammond MEH, Hayes DF, Dowsett M, et al (2010). American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 28, 2784-95. https://doi.org/10.1200/JCO.2009.25.6529
- Harris LN, Ismaila N, McShane LM, et al (2016). Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol, 34, 1134-50 https://doi.org/10.1200/JCO.2015.65.2289
- Jonat W, Arnold N (2011). Is the Ki-67 labelling index ready for clinical use?. Ann Oncol, 22, 500-2. https://doi.org/10.1093/annonc/mdq732
- Kennecke H, Yerushalmi R, Woods R, et al (2010). Metastatic behavior of breast cancer subtypes. J Clin Oncol, 28, 3271-7. https://doi.org/10.1200/JCO.2009.25.9820
- Pathmanathan N, Balleine RL (2013). Ki67 and proliferation in breast cancer. J Clin Pathol, 66, 512-6. https://doi.org/10.1136/jclinpath-2012-201085
- Petric M, Martinez S, Acevedo F, et al (2014). Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy. Asian Pac J Cancer Prev, 15, 10277-80.
- Sestak I, Cuzick J, Dowsett M, et al (2015). Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk. J Clin Oncol, 33, 916-22. https://doi.org/10.1200/JCO.2014.55.6894
- Shim HJ, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44. https://doi.org/10.7314/APJCP.2014.15.14.5539
- Sparano JA, Gray RJ, Makower DF, et al (2015). Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med, 373, 2005-14 https://doi.org/10.1056/NEJMoa1510764
- Turner N, Biganzoli L, Malorni L, et al (2013). Adjuvant chemotherapy: which patient? what regimen? Am Soc Clin Oncol Educ Book, 33, 3-8 https://doi.org/10.1200/EdBook_AM.2013.33.3
- Wolff AC, Hammond MEH, Hicks DG, et al (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol, 31, 3997-4013. https://doi.org/10.1200/JCO.2013.50.9984
- Zelnak AB, O'Regan RM (2013). Genomic subtypes in choosing adjuvant therapy for breast cancer. Oncology, 27, 204-10.